Health Care [ 9/12 ] | Biotechnology [ 43/74 ]
NASDAQ | Common Stock
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1.
Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor.
The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 3, 25 | 0.00 Increased by +100.00% | - |
| Aug 7, 25 | -0.18 Increased by +52.63% | - |
| Apr 30, 25 | -0.64 Decreased by -166.67% | -0.63 Decreased by -1.59% |
| Nov 27, 24 | 0.00 Increased by +100.00% | -0.62 Increased by +100.00% |
| Aug 8, 24 | -0.35 | -0.61 Increased by +42.62% |
| Feb 28, 24 | -0.38 | -0.38 |
| Nov 29, 23 | -0.24 | -0.24 |
| Aug 30, 23 | -1.94 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 745.00 K Increased by +N/A% | -13.81 M Increased by +78.22% | Decreased by -1.85 K% Decreased by N/A% |
| Mar 31, 24 | 745.00 K Increased by +N/A% | -13.81 M Increased by +8.09% | Decreased by -1.85 K% Decreased by N/A% |
| Dec 31, 23 | 2.50 M Increased by +N/A% | -13.23 M Increased by +40.19% | Decreased by -529.06% - |
| Sep 30, 23 | 2.50 M Increased by +N/A% | -13.23 M Increased by +40.19% | Decreased by -529.06% - |
| Jun 30, 23 | 0.00 Decreased by N/A% | -63.40 M Decreased by -1.72 K% | Decreased by N/A% - |
| Mar 31, 23 | 0.00 Decreased by N/A% | -15.02 M Decreased by -35.72% | Decreased by N/A% - |
| Dec 31, 22 | N/A - | -22.11 M - | - - |
| Sep 30, 22 | N/A - | -22.11 M - | - - |